Although our analysis included more than 300 cancer-relevant genes, additional parallels, and differences in the co-alteration landscape of KRAS and EGFR-mutant non-Sq NSCLC and across different ancestries are likely to continue to emerge along with future comprehensive sequencing efforts and evolving treatment landscape. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.